Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.68 |
| ▸ | TUBB | P07437 | 4/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.68 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.68 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.68 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.68 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.68 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.68 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.68 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.68 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.68 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.68 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.68 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28880774 | 0.90 | BRAF (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14022520 | 0.90 | GAA (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2977993 | 0.90 | MAPT (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29981081 | 0.90 | MAPT (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1967979 | 0.90 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1965853 | 0.90 | BRAF (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15152603 | 0.90 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15152588 | 0.86 | TUBB4A (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15152564 | 0.86 | MAPT (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28713723 | 0.86 | TUBB4A (0.93) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4284798-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-115286629-B | Method for preparing medicine intermediate 3-anilioimidazole [1,2-a ] pyridine derivative through catalysis | 安徽工业大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115286629-A | Method for preparing medical intermediate 3-phenylamino imidazole [1,2-a ] pyridine derivative through catalysis | 安徽工业大学 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022164934-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | PAK1, CDC42, CDC42BPG | TUBB4A 1138/4885TUBB 894/4885TUBA3C 1471/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | TUBB4A 3048/4885TUBB 2406/4885TUBA3C 2959/4885 |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | PAK1, CDC42, CDC42BPG | TUBB4A 1138/4885TUBB 894/4885TUBA3C 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.